Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V7YA
|
|||
| Former ID |
DCL000120
|
|||
| Drug Name |
GMX1777
|
|||
| Synonyms |
Teglarinad chloride; GMX1777; UNII-D6V5QYX9MZ; 432037-57-5; D6V5QYX9MZ; EB1627; 1-[[[[2-[2-[2-[2-Methoxyethoxy]ethoxy]ethoxy]ethoxy]carbonyl]oxy]methyl]-4-[N'-cyano-N''-[6-[4-chlorophenoxy]hexyl]guanidino]pyridinium chloride; Teglarinad chloride [USAN:INN]; GMX 1777; GMX-1777 chloride; CHEMBL190412; SCHEMBL2672343; CTK1D4865; Teglarinad chloride (USAN/INN); EB-1627; D09678
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Gemin X
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H43Cl2N5O8
|
|||
| Canonical SMILES |
COCCOCCOCCOCCOC(=O)OC[N+]1=CC=C(C=C1)NC(=NCCCCCCOC2=CC=C(C=C2)Cl)NC#N.[Cl-]
|
|||
| InChI |
1S/C30H42ClN5O8.ClH/c1-38-16-17-39-18-19-40-20-21-41-22-23-43-30(37)44-25-36-13-10-27(11-14-36)35-29(34-24-32)33-12-4-2-3-5-15-42-28-8-6-26(31)7-9-28;/h6-11,13-14H,2-5,12,15-23,25H2,1H3,(H,33,34);1H
|
|||
| InChIKey |
DAHMXVAETAAQOZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 432037-57-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nicotinamide phosphoribosyltransferase (NAMPT) | Target Info | Modulator | [1], [2] |
| BioCyc | NAD salvage | |||
| KEGG Pathway | Nicotinate and nicotinamide metabolism | |||
| Metabolic pathways | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| IL1 Signaling Pathway | ||||
| TCR Signaling Pathway | ||||
| Pathwhiz Pathway | Nicotinate and Nicotinamide Metabolism | |||
| Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
| WikiPathways | Adipogenesis | |||
| Metabolism of water-soluble vitamins and cofactors | ||||
| Circadian Clock | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-... Mol Cell Biol. 2009 Nov;29(21):5872-88. | |||
| REF 2 | Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.Cancer Res.2014 Nov 1;74(21):5948-54. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.